Legend Biotech on go with early-stage CAR-T candidate in blood cancer

 

• The FDA has signed-off Legend Biotech's (LEGN +11.1%) investigational new drug application to evaluate LB1901, an autologous chimeric antigen receptor T-cell (CAR-T) therapy, for the treatment of adults with relapsed or refractory T-cell lymphoma.
• Upcoming Phase 1 multicohort study will enroll patients with relapsed or refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma in the U.S., with primary objectives of the study are to characterize the safety and tolerability of LB1901 and to determine the recommended Phase 2 dose.
• LB1901 targets CD4, which is a surface membrane glycoprotein uniformly expressed in a majority of TCL subtypes.
• https://seekingalpha.com/news/3644107-legend-biotech-on-go-early-stage-stage-car-t-candidate-in-blood-cancer